Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Nutrients ; 12(3)2020 Feb 28.
Article in English | MEDLINE | ID: mdl-32121191

ABSTRACT

Fermentation has been applied to a multitude of food types for preservation and product enhancing characteristics. Interest in the microbiome and healthy foods makes it important to understand the microbial processes involved in fermentation. This is particularly the case for products such as fermented cashew (Anacardium occidentale). We hereby describe the characterisation of cashew samples throughout an entire fermentation production process, starting at the quinoa starter inoculum (rejuvelac). The viable bacterial count was 108 -109 colony forming units/g. The nutritional composition changed marginally with regards to fats, carbohydrates, vitamins, and minerals. The rejuvelac starter culture was predominated by Pediococcus and Weissella genera. The 'brie' and 'blue' cashew products became dominated by Lactococcus, Pediococcus, and Weissella genera as the fermentation progressed. Cashew allergenicity was found to significantly decrease with fermentation of all the end-product types. For consumers concerned about allergic reactions to cashew nuts, these results suggested that a safer option is for products to be made by fermentation.


Subject(s)
Allergens/chemistry , Anacardium/chemistry , Cheese/microbiology , Chenopodium quinoa/physiology , Fermentation , Food Microbiology , Nutritional Physiological Phenomena , Bacteria/isolation & purification , Colony Count, Microbial , Humans , Hydrogen-Ion Concentration , Microbiota
2.
Am J Health Syst Pharm ; 72(11 Suppl 1): S25-30, 2015 Jun 01.
Article in English | MEDLINE | ID: mdl-25991590

ABSTRACT

OBJECTIVE: The purpose of this study is to compare the incidence of acute renal injury (ARI) in patients on intermittent infusion to extended infusion piperacillin/tazobactam. METHODS: Data was collected for the intermittent infusion group from November 2010 to December 2010 until 100 patients were enrolled. The data was then compared to 100 patients in the extended infusion group from November 2011 to December 2011. Patients who received at least three consecutive doses of piperacillin/tazobactam and were inpatient for at least 48 hours were included. Patients were excluded for any of the following: baseline serum creatinine (SCr) ≥4 mg/dL, age less than 18 years old, pregnancy, penicillin allergy, or concurrent use with any cephalosporin or penicillin. The primary endpoint was the incidence of ARI, defined as a SCr two times the baseline or 0.5 mg/dL increase within 24 hours. The secondary endpoint was patient length of stay, measured as actual inpatient days. RESULTS: Eleven patients in the intermittent infusion group and nine patients in the extended infusion group developed ARI (11% vs. 9%, p = 0.637). The length of stay between the intermittent and extended infusion groups was 19 days vs. 14 days, respectively (p = 0.083). CONCLUSION: The incidence of ARI in patients on piperacillin/tazobactam was similar between the intermittent and extended infusion groups. Larger studies should be considered to confirm that the incidence of ARI associated with piperacillin/tazobactam is not infusion-related.


Subject(s)
Acute Kidney Injury/chemically induced , Anti-Bacterial Agents/adverse effects , Penicillanic Acid/analogs & derivatives , Acute Kidney Injury/epidemiology , Aged , Anti-Bacterial Agents/administration & dosage , Drug Administration Schedule , Female , Humans , Incidence , Infusions, Intravenous , Longevity , Male , Middle Aged , Penicillanic Acid/administration & dosage , Penicillanic Acid/adverse effects , Piperacillin/administration & dosage , Piperacillin/adverse effects , Piperacillin, Tazobactam Drug Combination , Retrospective Studies
3.
Biotechnol Biofuels ; 5: 5, 2012 Feb 08.
Article in English | MEDLINE | ID: mdl-22316115

ABSTRACT

BACKGROUND: There is currently considerable interest in developing renewable sources of energy. One strategy is the biological conversion of plant biomass to liquid transportation fuel. Several technical hurdles impinge upon the economic feasibility of this strategy, including the development of energy crops amenable to facile deconstruction. Reliable assays to characterize feedstock quality are needed to measure the effects of pre-treatment and processing and of the plant and microbial genetic diversity that influence bioconversion efficiency. RESULTS: We used the anaerobic bacterium Clostridium phytofermentans to develop a robust assay for biomass digestibility and conversion to biofuels. The assay utilizes the ability of the microbe to convert biomass directly into ethanol with little or no pre-treatment. Plant samples were added to an anaerobic minimal medium and inoculated with C. phytofermentans, incubated for 3 days, after which the culture supernatant was analyzed for ethanol concentration. The assay detected significant differences in the supernatant ethanol from wild-type sorghum compared with brown midrib sorghum mutants previously shown to be highly digestible. Compositional analysis of the biomass before and after inoculation suggested that differences in xylan metabolism were partly responsible for the differences in ethanol yields. Additionally, we characterized the natural genetic variation for conversion efficiency in Brachypodium distachyon and shrub willow (Salix spp.). CONCLUSION: Our results agree with those from previous studies of lignin mutants using enzymatic saccharification-based approaches. However, the use of C. phytofermentans takes into consideration specific organismal interactions, which will be crucial for simultaneous saccharification fermentation or consolidated bioprocessing. The ability to detect such phenotypic variation facilitates the genetic analysis of mechanisms underlying plant feedstock quality.

4.
Clin Cancer Res ; 9(9): 3282-7, 2003 Aug 15.
Article in English | MEDLINE | ID: mdl-12960113

ABSTRACT

PURPOSE: The effects of a low-fat diet or a low-fat diet with the addition of a soy supplement were investigated in a pilot Phase II study for asymptomatic, hormonally naive prostate cancer patients with rising prostate-specific antigen (PSA) levels. EXPERIMENTAL DESIGN: A two-step intervention was implemented. During step 1 patients were begun on a low-fat diet with a goal to reduce fat intake to 15% of total daily calories. On PSA progression, a soy protein supplement was added to the diet (step 2). The primary end point was PSA reduction by 50%. Secondary end points were PSA doubling time and time to progression (TTP). Serum was analyzed for changes in the sex hormone and insulin-like growth factor (IGF-I) axes. RESULTS: Among 18 evaluable patients, (median follow-up on study 10.5 months), no patient on either step had a PSA reduction by 50% at any time. There was a trend toward a longer PSA doubling time (P = 0.06) and a prolongation in estimated median TTP of approximately 3 months (P = 0.018) during step 2 compared with step 1 of the study. During step 1, free testosterone levels decreased by 5% (P < 0.01), and during step 2, IGF-I levels increased by 22% (P = 0.02). CONCLUSIONS: A low-fat diet with the subsequent addition of a soy supplement did not result in a significant decline in PSA levels. The addition of soy protein had a modest effect on TTP. A potentially undesirable effect associated with the administration of soy was an increase in IGF-I serum levels.


Subject(s)
Diet , Dietary Fats , Prostate-Specific Antigen/biosynthesis , Prostatic Neoplasms/diet therapy , Soybean Proteins/pharmacology , Aged , Carbohydrate Metabolism , Dietary Fats/metabolism , Humans , Insulin-Like Growth Factor I/biosynthesis , Male , Middle Aged , Pilot Projects , Prostate-Specific Antigen/blood , Testosterone/blood , Thymine Nucleotides , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...